1. Home
  2. TOVX vs EVGN Comparison

TOVX vs EVGN Comparison

Compare TOVX & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theriva Biologics Inc.

TOVX

Theriva Biologics Inc.

SELL

Current Price

$0.21

Market Cap

11.1M

Sector

Health Care

ML Signal

SELL

Logo Evogene Ltd

EVGN

Evogene Ltd

HOLD

Current Price

$0.40

Market Cap

11.1M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOVX
EVGN
Founded
2001
1999
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Agricultural Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
11.1M
11.1M
IPO Year
2012
2013

Fundamental Metrics

Financial Performance
Metric
TOVX
EVGN
Price
$0.21
$0.40
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $2.50
N/A
AVG Volume (30 Days)
★ 373.1K
297.9K
Earning Date
08-11-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 89.07
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$81.06
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.35
52 Week High
$0.85
$1.33

Technical Indicators

Market Signals
Indicator
TOVX
EVGN
Relative Strength Index (RSI) 40.19 39.55
Support Level $0.17 $0.36
Resistance Level $0.25 $0.86
Average True Range (ATR) 0.01 0.04
MACD -0.00 0.00
Stochastic Oscillator 2.05 24.73

Price Performance

Historical Comparison
TOVX
EVGN

About TOVX Theriva Biologics Inc.

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.

About EVGN Evogene Ltd

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the industrial segment, followed by Agriculture.

Share on Social Networks: